Notizie AIOM – anno XV
Liquid biopsy genotyping in lung cancer: ready for clinical utility?
Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its potential to detect ...Leggi tutto
ASCO Statement: President’s Budget Will Devastate U.S. Research Enterprise
March 16, 2017 - ASCO President Daniel F. Hayes, MD, FACP, FASCO, released the following statement today: “We soundly oppose President Trump's budget outline, which would cut $6 billion from the National Institutes of Health (NIH). Reducing NIH's funding by nearly ...Leggi tutto
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
The randomized, phase 3 CheckMate 025 study of nivolumab (n=410) versus everolimus (n=411) in previously treated adults (75% male; 88% white) with advanced renal cell carcinoma (aRCC) demonstrated significantly improved overall survival (OS) and objective response rate (ORR). ...Leggi tutto
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue. A Meta-analysis
Cancer-related fatigue (CRF) remains one of the most prevalent and troublesome adverse events experienced by patients with cancer during and after therapy. To perform a meta-analysis to establish and compare the mean weighted effect sizes (WESs) of the 4 most commonly recommended ...Leggi tutto
ASCO Honors Researchers and Scientists for Significant Advancements in Cancer Treatment and Care
March 14, 2017 - ASCO and the Conquer Cancer Foundation of ASCO (CCF) have proudly announced the winners of ASCO's Special Awards, the Society's highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient ...Leggi tutto
Cancer Care Ontario and ASCO Clinical Practice Guideline: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
March 15, 2017 - As reported in the Journal of Clinical Oncology by Dhesy-Thind, of Juravinski Cancer Centre, Hamilton Health Sciences, and colleagues, Cancer Care Ontario and ASCO have issued a clinical practice guideline on the use of adjuvant bisphosphonates and other ...Leggi tutto
FDA Approves Pembrolizumab for Hodgkin Lymphoma
March 14, 2017 - The FDA has granted an accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with classical Hodgkin lymphoma (cHL) who are refractory or have relapsed after 3 or more lines of therapy. The approval is based on data from ...Leggi tutto
Management of Patients With Stage I Lung Cancer
The treatment of stage I non–small-cell lung cancer has advanced markedly over the past century. The transition from therapeutic nihilism with ensured mortality to radical surgery with pneumonectomy to rational oncologic-based resection has resulted in dramatically ...Leggi tutto